Oncologist Advisory Board Member

Oncologist Advisory Board Member This advisory role is designed for nationally respected oncologists who bring deep expertise in clinical governance, multidisciplinary cancer program development, quality oversight, and health system strategy. The position supports the advancement of structured, high-performing oncology service lines within evolving and growth oriented healthcare environments. While clinical expertise may span solid tumors, hematologic malignancies, precision oncology, immunotherapy, cellular therapies, survivorship, and palliative integration, the oncologist’s perspective is essential in shaping standardized diagnostic pathways, evidence-based treatment algorithms, biomarker driven care models, clinical trial integration, infusion and pharmacy frameworks, and population based oncology strategies. As an Oncologist Advisory Board Member, you will provide strategic oversight to ensure expanding oncology programs uphold clinical rigor, NCCN-aligned standards, operational scalability, regulatory compliance, accreditation readiness, and measurable patient outcomes. This role partners closely with executive leadership, surgical and radiation oncology, pathology, radiology, pharmacy leadership, genetics, primary care networks, hospital operations, quality committees, and data strategy teams to strengthen governance frameworks and support responsible, performance driven growth. The advisory focuses on building sustainable, patient-centered oncology models that balance therapeutic innovation with safety, compliance, financial stewardship, and enterprise-wide accountability across outpatient infusion centers, hospital-based oncology services, academic collaborations, community oncology networks, and integrated delivery systems. This position is ideal for a physician leader committed to advancing system level excellence in cancer care, strengthening quality transparency, optimizing multidisciplinary collaboration, expanding access to evidence-based therapies and clinical trials, and ensuring the long-term sustainability of oncology programs within modern healthcare systems. About Alzheimer’s Treatment Centers of America (ATCA) Alzheimer’s Treatment Centers of America (ATCA) leverages Artificial Intelligence (AI) and Personalized Precision Medicine to transform the treatment of Alzheimer’s disease, dementia, and cognitive impairment, including brain fog associated with Long COVID. This is about delivering structured, data driven treatment to patients today. ATCA goes beyond traditional diagnosis to identify underlying contributors to neurodegeneration and cognitive dysfunction, implementing individualized treatment protocols designed to slow progression and improve functional outcomes. Our multidisciplinary leadership team includes experienced healthcare executives, neuroscientists, AI engineers, and clinical specialists working together to deploy a scalable, neurologist supported clinic model nationwide. As we expand, we are building a governance framework supported by senior physician leaders who understand clinical rigor, operational scalability, and health system integration. Why Now? Growing Community Need: Our Palm Beach Gardens/Jupiter clinic is fully operational and actively treating patients in a high visibility medical corridor adjacent to Cleveland Clinic. Originally launched in a former urgent care space to enable rapid deployment, the clinic reached capacity quickly, with appointments booked months in advance reflecting significant unmet demand for proactive cognitive care. Three additional clinics are in development, with broader national expansion underway. ATCA is building a repeatable, specialist supported specialty model that expands access to structured cognitive evaluation and longitudinal management while maintaining clinical rigor and operational scalability. Seamless System Integration: ATCA’s care model integrates within the existing healthcare ecosystem. Treatments are reimbursed by Medicare, Medicare Advantage, and most major commercial insurers, reducing barriers to access and accelerating patient adoption. Focused on Outcomes: In a study utilizing ATCA’s AI driven protocol, 75% of patients with mild cognitive impairment demonstrated no further cognitive decline. This represents a data driven, proactive approach that complements traditional management pathways and emphasizes measurable outcomes. Advanced Therapeutic Options: Eligible patients may have access to TB006, an FDA approved therapy available for compassionate use, providing a potential treatment pathway for certain dementias, including Alzheimer’s disease. Physician Supported: ATCA’s protocols are backed by an experienced Medical Advisory Board of top doctors and scientists. As we expand nationally, we are strengthening this advisory infrastructure with senior surgical leaders who bring expertise in clinical governance, quality assurance, scalability, and system-based care delivery. See our Medical Advisory Board: Key Achievements Proprietary AI Precision Engine: ATCA has built and deployed a defensible AI driven precision medicine platform that optimizes Alzheimer’s treatment at the individual patient level, creating strong clinical differentiation and long-term data network effects. High Margin, Replicable Clinic Model: Engineered a scalable specialty clinic platform targeting 44% EBITDA margins, driven by optimized staffing ratios, high-acuity service mix, and strong reimbursement dynamics designed for rapid multi-market expansion. Massive, Underserved Market Opportunity: Positioned to capture share in a $355B U.S. Alzheimer’s market and a $1.5T global opportunity, addressing one of the largest and fastest-growing unmet needs in healthcare. Embedded Revenue Generating Research Infrastructure: Integrated micro research capabilities within each clinic to generate real world evidence, pharmaceutical partnerships, clinical trial participation, and recurring high margin ancillary revenue streams. Responsibilities Include Clinical Governance & Oversight: Provide strategic advisory leadership to ensure evidence-based, standardized diagnostic and treatment pathways across solid tumors and hematologic malignancies, including precision oncology, immunotherapy, targeted therapies, cellular therapies, survivorship, and palliative integration. Ensure alignment with NCCN guidelines, CMS requirements, accreditation standards (e.g., CoC, NAPBC), and regulatory compliance while reinforcing clinical rigor, patient safety, biomarker stewardship, and quality consistency across the oncology continuum. Service Line Strategy & Scalability: Advise on the structured development, optimization, and responsible expansion of oncology service lines, including outpatient infusion centers, hospital-based oncology programs, multidisciplinary tumor boards, precision medicine programs, clinical trial infrastructure, and community oncology network integration. Support sustainable growth models that enhance access to advanced therapies, operational efficiency, care standardization, and equitable delivery across integrated health systems. Quality & Outcomes Leadership: Guide the implementation of standardized oncology quality metrics, pathway adherence frameworks, biomarker testing benchmarks, treatment appropriateness criteria, patient-reported outcomes, registry participation, and performance reporting aligned with value-based oncology care and population health objectives. Promote transparency in outcomes measurement and continuous quality improvement initiatives. Interdisciplinary & Executive Collaboration: Partner with executive leadership, surgical and radiation oncology, pathology, radiology, pharmacy leadership, genetics, palliative care, nursing, infusion services, ambulatory operations, and quality committees to ensure coordinated, patient-centered cancer care delivery and strong governance structures that support multidisciplinary excellence. Innovation, Risk & Reimbursement Strategy: Provide oversight on emerging therapeutic innovations, companion diagnostics, digital oncology platforms, AI-supported clinical decision tools, clinical trial expansion strategies, regulatory considerations, documentation standards, and reimbursement models. Support scalable growth while safeguarding clinical integrity, accreditation readiness, financial stewardship, and enterprise-wide accountability across oncology programs. Why Join Us? Strategic Influence: Shape the governance architecture of rapidly expanding AI enabled brain health platforms. Board Level Engagement: Contribute at the advisory level without day to day operational responsibility. Impact at Scale: Help ensure innovative cognitive care models expand responsibly while preserving the highest standards of neurosurgical oversight. Enterprise Level Perspective: Apply surgical leadership experience to one of the most urgent and fastest growing areas in healthcare. Clinical Integrity During Innovation: Safeguard rigor, accountability, and patient safety as precision medicine platforms scale nationally. Compensation / Perks Equity Participation Opportunities: Select advisory roles may include equity options aligned with long term strategic contribution. Strategic Investment Access: Advisory members may be offered optional participation in growth financing initiatives where applicable. Equal Opportunity Commitment We are committed to fostering inclusive advisory leadership. Diverse perspectives strengthen governance, innovation, and patient outcomes. Senior surgeons from all backgrounds are encouraged to participate in shaping the future of structured, scalable brain health care.

Created: 2026-03-06